Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.

Dihge, Looket ; Bendahl, Pär-Ola LU ; Grabau, Dorthe LU ; Isola, Jorma ; Lövgren, Kristina LU ; Rydén, Lisa LU orcid and Fernö, Mårten LU (2008) In Breast Cancer Research and Treatment 109(2). p.255-262
Abstract
The epidermal growth factor receptor (EGFR) and the estrogen receptor (ER) modulator Amplified In Breast cancer-1 (AIB1) have been reported to be of importance for the prognosis of breast cancer patients. We have analyzed AIB1 and EGFR by immunohistochemistry in primary breast cancers (n = 297) arranged in a tissue microarray in order to predict outcome after adjuvant endocrine therapy with tamoxifen for two years. High expression of AIB1 was associated with DNA-nondiploidy, high S-phase fraction, HER2 amplification, and short term (≤2 years) distant disease-free survival (DDFS), independent of ER status. High expression of EGFR was strongly associated to ER negativity and also correlated with progesterone receptor negativity, high S-phase... (More)
The epidermal growth factor receptor (EGFR) and the estrogen receptor (ER) modulator Amplified In Breast cancer-1 (AIB1) have been reported to be of importance for the prognosis of breast cancer patients. We have analyzed AIB1 and EGFR by immunohistochemistry in primary breast cancers (n = 297) arranged in a tissue microarray in order to predict outcome after adjuvant endocrine therapy with tamoxifen for two years. High expression of AIB1 was associated with DNA-nondiploidy, high S-phase fraction, HER2 amplification, and short term (≤2 years) distant disease-free survival (DDFS), independent of ER status. High expression of EGFR was strongly associated to ER negativity and also correlated with progesterone receptor negativity, high S-phase fraction, and inversely correlated with nodal metastases. In univariate analysis, high EGFR was associated with shorter DDFS (hazard ratio 2.1; P = 0.017), and reached borderline significance in a multivariate analysis, adjusting for ER, menopausal and lymph node status, tumor size, and HER2 (P = 0.057).

In conclusion, both AIB1 and EGFR were associated to DDFS for breast cancer patients treated with two years of adjuvant tamoxifen; AIB1 with the development of early distant recurrences, indicating association between high AIB1 and resistance to tamoxifen during treatment, and EGFR with distant recurrences up to a follow up of five years. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
EGFR, estrogen, AIB1, adjuvant, tamoxifen
in
Breast Cancer Research and Treatment
volume
109
issue
2
pages
255 - 262
publisher
Springer
external identifiers
  • wos:000255954200007
  • scopus:43149090547
  • pmid:17636398
ISSN
1573-7217
DOI
10.1007/s10549-007-9645-1
language
English
LU publication?
yes
additional info
The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Oncology, MV (013035000), Surgery (Lund) (013009000), Pathology, (Lund) (013030000)
id
af0b1fc4-b9e5-4b80-8210-166e8fce45ea (old id 540661)
alternative location
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17636398&dopt=Abstract
date added to LUP
2016-04-01 14:26:44
date last changed
2022-04-06 18:39:44
@article{af0b1fc4-b9e5-4b80-8210-166e8fce45ea,
  abstract     = {{The epidermal growth factor receptor (EGFR) and the estrogen receptor (ER) modulator Amplified In Breast cancer-1 (AIB1) have been reported to be of importance for the prognosis of breast cancer patients. We have analyzed AIB1 and EGFR by immunohistochemistry in primary breast cancers (n = 297) arranged in a tissue microarray in order to predict outcome after adjuvant endocrine therapy with tamoxifen for two years. High expression of AIB1 was associated with DNA-nondiploidy, high S-phase fraction, HER2 amplification, and short term (≤2 years) distant disease-free survival (DDFS), independent of ER status. High expression of EGFR was strongly associated to ER negativity and also correlated with progesterone receptor negativity, high S-phase fraction, and inversely correlated with nodal metastases. In univariate analysis, high EGFR was associated with shorter DDFS (hazard ratio 2.1; P = 0.017), and reached borderline significance in a multivariate analysis, adjusting for ER, menopausal and lymph node status, tumor size, and HER2 (P = 0.057).<br/><br>
In conclusion, both AIB1 and EGFR were associated to DDFS for breast cancer patients treated with two years of adjuvant tamoxifen; AIB1 with the development of early distant recurrences, indicating association between high AIB1 and resistance to tamoxifen during treatment, and EGFR with distant recurrences up to a follow up of five years.}},
  author       = {{Dihge, Looket and Bendahl, Pär-Ola and Grabau, Dorthe and Isola, Jorma and Lövgren, Kristina and Rydén, Lisa and Fernö, Mårten}},
  issn         = {{1573-7217}},
  keywords     = {{EGFR; estrogen; AIB1; adjuvant; tamoxifen}},
  language     = {{eng}},
  number       = {{2}},
  pages        = {{255--262}},
  publisher    = {{Springer}},
  series       = {{Breast Cancer Research and Treatment}},
  title        = {{Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.}},
  url          = {{https://lup.lub.lu.se/search/files/3978499/626064.pdf}},
  doi          = {{10.1007/s10549-007-9645-1}},
  volume       = {{109}},
  year         = {{2008}},
}